Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HALCYON BIOMEDICAL INC
- Proposal award date
- 2016-09-06
- Contract end date
- 2019-06-30
- UEI
- C15ACBHQ4P67
- Solicitation number
- HL14-010
- Topic code
- NHLBI
Research abstract
PROJECT SUMMARY ABSTRACT
More than of the global burden of sickle cell disease SCD is carried by the low income developing
countries of sub Saharan Africa where incidence at birth can be as high as for SCD and for sickle
trait SCD is particularly lethal to young children accounting for up to of under mortality in countries
with the highest prevalence of the disease Data from pilot programs in Africa demonstrate that most of these
deaths can be prevented with inexpensive treatments e g penicillin prophylaxis pneumococcal
immunizations malaria bed nets and education about the importance of seeking medical attention for fever
provided SCD could be diagnosed early in life In our Phase I work we have successfully developed a simple
and inexpensive paper based test for the diagnosis of SCD in infants and young children andgt months old Our
test enables the diagnosis via visual interpretation of the stain pattern produced on chromatography paper by a
droplet of blood mixed with hemoglobin Hb solubility buffer The current version of the paper based SCD test
kit is completely equipment and electricity free requires only a L blood sample costs andlt $ per test can
be completed in min and is unaffected by severe anemia high HbF elevated ambient temperature or
humidity It has a limit of detection of andlt HbS and was able to detect the presence of any HbS sickle cell
trait or disease in patient samples with sensitivity and specificity in a pre clinical study in a resource
limited setting n Cabinda Angola In our laboratory the test was able to diagnose SCD with
sensitivity and specificity n In Phase II we propose to develop a complete self contained
diagnostic kit and to demonstrate its diagnostic accuracy in a pivotal clinical trial across multiple sites in
several countries in sub Saharan Africa We will first evaluate the feasibility of using a prototype kit for
diagnosing SCD in the target patient population of children presenting with acute illness to Hospital Provincial
de Cabinda We will also collect input on design and usability of the test s components and instructions from
the site personnel to inform parallel development of the finished marketable diagnostic kit We will then work
with our contract manufacturing partners to develop a version of the diagnostic kit that is optimized for mass
production regulatory trials and subsequent marketing This iterative process will be continually informed by
research and development in our laboratory the usability data from the Cabinda site and advice from our
marketing and distribution partners Finally we will demonstrate the diagnostic accuracy of the finished
marketable SCD test kit in a pivotal clinical trial in sub Saharan Africa We have to date identified well
qualified clinical sites Morogoro Tanzania Bamako Mali Lusaka Zambia Ibadan Nigeria and Cabinda
Angola each highly interested in participating in our trial We will work closely with our Steering Committee
and the FDA to finalize the design of the proposed trial Public Health Relevance
Most children born with sickle cell disease in sub Saharan Africa die in early childhood from causes that could
be easily prevented through simple and inexpensive prophylaxis if their disease was diagnosed soon after
birth Universal screening of newborns is impractical in low income countries due to a large number of out of
hospital births and the prohibitive cost of conventional testing methods This highly innovative project plans to
develop and commercialize an ultra low cost paper based diagnostic test for sickle cell disease to enable
screening infants and young children during their first visit to a local clinic
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
9 SBIR/STTR records share this UEI (1992–2020). Reported award amounts total $3,696,303. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Agriculture
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards